ThermoGenesis Holdings: Falls after Q2 revenue nearly halves

Article content

** Shares of cell-based therapy co fall as much as 20.7% to $3.75 in early trade – lowest in more than 4 months

** Co, on Friday, posted Q2 rev of $2.2 mln, nearly half from a year earlier; attributed decline to low demand for its proprietary AXP disposable blood processing sets

** THMO posted loss of $2.6 mln vs profit of $2 mln a year earlier; co said loss was driven by inventory reserve of ~$3.6 mln for remaining on-hand COVID-19 testing kits from ImmuneCyte recognized during quarter

** THMO becomes second-worst performer on NASDAQ

** YTD, stock up 7.5%

(Reporting by Shreyasee Raj in Bengaluru)